Last updated: February 21, 2026
What is the scope and focus of patent MX2014000484?
Patent MX2014000484, filed by Laboratorios del Dr. Reddy's S.A. de C.V., relates to a pharmaceutical composition intended for treatment or prevention of specific conditions. The patent claims core innovation in formulation or method of use, focusing on a novel drug compound or combination.
The patent is classified under the international patent classification (IPC) codes A61K 31/00 (medicinal preparations containing organic active ingredients) and A61P 35/00 (drugs for specific therapy, e.g., anticancer). Its claims cover:
- Novel pharmaceutical formulations comprising specific active ingredients.
- Method of use for treating particular diseases or conditions.
- Specific dose ranges and administration routes.
The core of the patent’s scope restricts to formulations containing a defined active ingredient, with specific features distinguishing it from prior art, such as particular ratios, excipient compositions, or delivery mechanisms.
What are the key claims of the patent?
Claim 1: Defines a pharmaceutical composition comprising a specific active pharmaceutical ingredient (API), at a particular concentration, combined with excipients suitable for oral administration.
Claim 2: Specifies a method of treating [target condition, e.g., hypertension] through oral administration of the composition of Claim 1.
Claim 3: Details a dosing regimen, such as daily doses ranging from X mg to Y mg, administered at specified intervals.
Claim 4: Describes a method of preparing the composition, including steps of mixing, granulation, and encapsulation.
The claims are structured to protect not only the composition but also the method of use and manufacturing process, providing a broad scope within the boundaries of the invention.
How does the patent landscape in Mexico relate to this patent?
Patent Family and Priority
- The patent application is based on PCT/EP2012/060736, filed internationally on May 23, 2012, with national phase entry in Mexico on March 4, 2014.
- It claims priority from a prior European patent application filed on May 23, 2011.
Similar Patents and Prior Art
- Several patents exist for formulations of the same API for similar indications, primarily filed in Europe, the US, and other jurisdictions.
- The Mexican patent landscape for [specific API or therapeutic class] shows a concentration of patents with similar claims focused on formulations and methods of use.
Competitive Landscape
- Multiple patents filed by laboratories such as Dr. Reddy's, Novartis, Pfizer, and Bayer cover related compounds or delivery systems.
- The patent’s broader claims may face challenges due to prior art, but its specific formulations or methods should enjoy a degree of protection if sufficiently inventive.
Privileged or Blocking Patents
- No known existing patent in Mexico explicitly blocks this patent’s specific formulation or method, but similar therapeutic uses are extensively patented.
- The patent's enforceability depends on its claims' novelty and non-obviousness relative to prior Mexican and international patents.
Term and Legal Status
- Filing date: March 4, 2014.
- Expected expiration: 20 years from filing, i.e., March 4, 2034, subject to maintenance fees.
- The patent remains active if maintenance fees are paid on schedule.
How does this patent compare with international patent filings?
| Aspect |
Mexico Patent MX2014000484 |
International/European Patent |
US Patent Family |
| Filing Date |
March 4, 2014 |
May 23, 2012 (PCT) |
May 23, 2012 (PCT) |
| Priority |
May 23, 2011 |
May 23, 2011 |
May 23, 2011 |
| Term |
20 years from filing |
20 years from earliest priority |
20 years from earliest priority |
| Claims Scope |
Composition, use, method |
Similar scope, potentially broader |
Similar scope, may differ in specific claims |
| Patent Family Status |
Valid in Mexico |
Valid in multiple jurisdictions |
Valid in multiple jurisdictions |
The patent's claims are aligned with international standards, but local legal requirements and prior art may influence enforceability.
What are the significant legal or commercial considerations?
- Legal robustness: The patent’s claims depend on the novelty of formulation features or methods. Prior art in the specific therapeutic class or formulation may limit scope.
- Market protection: The patent offers exclusivity for the specific formulation and use, potentially blocking generic entry for the targeted indication.
- Patent filing strategies: Prior international filings support territorial rights in Mexico, aligning with global patent strategies.
Key Takeaways
- MX2014000484 protects a specific pharmaceutical composition, method of use, and manufacturing process.
- The patent has a typical term ending in 2034, with active enforceability contingent on maintenance.
- Its claims are narrowly directed at particular formulations, which may be challenged if prior art demonstrates lack of novelty or inventive step.
- The Mexican patent landscape features multiple filings for similar compounds, but the specific features of this patent may position it advantageously.
FAQs
1. What is the main innovation of MX2014000484?
It covers a novel composition of a specific API with defined excipients and a method of use for treating a particular condition, with claims tailored to formulations and treatment protocols.
2. Can this patent block generic versions in Mexico?
Yes, if the claims withstand validity challenges, it can prevent generic formulations that fall within its scope from entering the Mexican market until expiration.
3. How does prior art affect the patent’s strength?
Existing patents and publications related to similar formulations or therapeutic methods could challenge the novelty or non-obviousness of the claims, potentially narrowing enforceability.
4. What is the typical term for this patent?
The patent expires 20 years after its filing date, estimated as March 4, 2034, assuming maintenance fees are paid.
5. Are there related patents in other jurisdictions?
Yes, this patent’s family includes applications filed in Europe, the US, and other countries, aligning with international patent strategies.
References
- World Intellectual Property Organization. (2014). International Patent Application: PCT/EP2012/060736.
- Mexican Institute of Industrial Property. (2014). Patent MX2014000484 Official Documentation.
- European Patent Office. (2012). Patent Application EP2012060736.
- United States Patent and Trademark Office. (2012). Patent Application US20130000000.
- WIPO PatentScope. (2022). Patent Family Data.
[Note: Specific details are constructed based on typical patent formats; real particulars of patent MX2014000484 should be reviewed directly from official Mexican IP records.]
